Neovascular eye diseases cause blindness, but underlying drivers are unclear. Here, the authors show that PRL3 promotes pathological angiogenesis, and that targeting PRL3 with an antibody therapy could offer a new treatment for ocular neovascularization.
- Koon Hwee Ang
- Min Thura
- Qi Zeng